Core Insights - The article discusses recent activities on the Hong Kong Stock Exchange, including companies filing for IPOs, passing hearings, and listing. Group 1: Companies Filing for IPOs - Two companies filed for IPOs: Dongfang Yanmei and NobiKan Technology [2][3] - Dongfang Yanmei focuses on regenerative medical devices and special medical foods, with projected revenues of RMB 128.82 billion and RMB 145.20 billion for 2023 and 2024, respectively, and net losses of RMB 63.51 million and RMB 69.38 million [2] - NobiKan Technology specializes in AI technologies and digital twin applications, with expected revenues of approximately RMB 253 million, RMB 364 million, and RMB 403 million from 2022 to 2024, and net profits of RMB 63.16 million, RMB 88.57 million, and RMB 115 million during the same period [3] Group 2: Companies Passing Hearings - Three companies passed the hearing: Mirxes, Shouhui Group, and MetaLight Inc. [4][6] - Mirxes, a miRNA technology company, aims to provide disease screening solutions in Asia, with revenues of approximately USD 17.76 million, USD 24.19 million, and USD 20.28 million from 2022 to 2024 [5] - Shouhui Group is a leading online insurance intermediary in China, with revenues of RMB 806 million, RMB 1.634 billion, and RMB 1.387 billion from 2022 to 2024 [7] - MetaLight Inc. operates a real-time bus information platform, achieving revenues of RMB 135 million, RMB 175 million, and RMB 206 million from 2022 to 2024 [8] Group 3: Companies Launching IPOs - Four companies are currently in the process of launching IPOs: Green Tea Group, CATL, Heng Rui Medicine, and Mirxes [9][10][11][12] - Green Tea Group's IPO was priced at HKD 7.19 per share, with a market capitalization of approximately HKD 4.236 billion upon listing [14] - CATL's IPO was priced at HKD 263.00 per share, with a subscription rate of nearly 120 times [10] - Heng Rui Medicine plans to offer shares at a price not exceeding HKD 44.05, with expectations to list on May 23, 2025 [11]
一周港股IPO：东方妍美、诺比侃递表；Mirxes、手回集团、元光科技通过聆讯